Gsk (GSK) Debt to Equity (2016 - 2025)
Gsk has reported Debt to Equity over the past 12 years, most recently at -$1.23 for Q4 2025.
- For Q4 2025, Debt to Equity fell 198.96% year-over-year to -$1.23; the TTM value through Dec 2025 reached -$1.23, down 198.96%, while the annual FY2025 figure was -$1.23, 198.96% down from the prior year.
- Debt to Equity for Q4 2025 was -$1.23 at Gsk, down from $1.24 in the prior quarter.
- Over five years, Debt to Equity peaked at $1.73 in Q4 2022 and troughed at -$1.23 in Q4 2025.
- A 5-year average of $0.9 and a median of $1.35 in 2023 define the central range for Debt to Equity.
- Biggest five-year swings in Debt to Equity: increased 20.74% in 2022 and later crashed 198.96% in 2025.
- Year by year, Debt to Equity stood at $1.43 in 2021, then grew by 20.74% to $1.73 in 2022, then dropped by 21.98% to $1.35 in 2023, then fell by 8.1% to $1.24 in 2024, then crashed by 198.96% to -$1.23 in 2025.
- Business Quant data shows Debt to Equity for GSK at -$1.23 in Q4 2025, $1.24 in Q4 2024, and $1.35 in Q4 2023.